Nutraceuticals Recommendations

Avivagen Inc.

David Bautz, Zacks Small-Cap Research (6/14/21) "We are very encouraged how VIV continues to expand its customer base and increase the size and frequency of orders for OxC-beta Livestock."

Joseph Gomes, Noble Capital Markets (5/4/21) "We believe VIV is at an inflection point with significant sales increases just around the corner and presents a favorable risk/reward proposition."

SmallCapsDaily (7/23/20) "VIV is building a compelling growth story as it has gone on to receive numerous country approvals across many large livestock markets in the world."

Clive Maund, CliveMaund.com (5/11/19) "This looks like an excellent point to buy back VIV."

Stellar Biotechnologies Inc.

The Life Sciences Report Interview with Pierre Erwes (12/9/15) "SBOT is one of my favorites."

MusclePharm Corp.

Mark Phillips, Seeking Alpha (12/16/14) "MSLP stock is deeply oversold at current levels."

The Life Sciences Report Interview with Dick Huebner (11/20/14) "MSLP has definitely proven itself a very capable marketing machine."

Chris Katje, Seeking Alpha (6/27/14) "International sales continue to be a focus for MSLP and a reason for further bullishness."

Boris Marjanovic, Seeking Alpha (5/7/14) "MSLP's robust growth and ramping margins make the stock a bargain."

ACP Investor, Seeking Alpha (3/12/14) "MSLP's strong Q4/13 growth in net sales shows new product launches and distribution deals are gaining traction."

Keay Nakae, Ascendiant Capital Markets (1/2/14) "Given MSLP's current stock price and market capitalization, management intends to uplist the stock to NASDAQ."

ACP Investor, Seeking Alpha (12/18/13) "MSLP shares appear to be significantly undervalued."

The Behavioral Economist, Seeking Alpha (11/19/13) "MSLP is a young, award winning, ever expanding company, competing in an extremely profitable market."

Devon Shire, Seeking Alpha (11/19/13) "MSLP has been growing at a breakneck speed."

The Life Sciences Report Interview with Brian Wilson (10/10/13) "MSLP has a prominent brand, and operates in a niche market that has been built largely on brand association."

The Life Sciences Report Interview with Keay Nakae (9/19/13) "MSLP has established a brand name people have gravitated to; we've seen really rapid revenue growth."

Kelvin M., Seeking Alpha (8/15/13) "MSLP is continuing to increase sales at a blistering pace."

Keay Nakae, Ascendiant Capital Markets (8/15/13) "We expect MSLP's sales will be boosted by the launch of its FitMiss and Arnold Schwarzenegger product lines."

MTF Investing, Seeking Alpha (7/3/13) "MSLP has a solid management team that understands the industry and the customer."

Buffett Junior, Seeking Alpha (6/18/13) "MSLP is significantly undervalued considering its growth potential."

Buffett Junior, Seeking Alpha (4/25/13) "Even when using conservative estimates, MSLP's upside potential is huge."